ClinicalTrials.gg
RecruitingNCT07160686THROMBO-STOPUpdated Sep 28, 2026

Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment

A Phase 3 interventional study of Apixaban and Placebo in Thromboprophylaxis, sponsored by University of Birmingham. Recruiting at 8 sites in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by University of Birmingham · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Sep 28, 2026Now RecruitingStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,456
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

The aim of this trial is to find out if a tablet called apixaban can reduce blood clots in people with lung cancer having chemotherapy or similar treatments. Apixaban is a type of oral anticoagulant ("blood thinner") that makes the blood less sticky to prevent blood clots forming.

The trial is trying to find out if apixaban it can reduce blood clots in people with lung cancer.

Participants will receive the following treatment:

  • Apixaban or placebo, 2.5mg taken by mouth twice a day for 6 months. This treatment will be taken in addition to any treatment that they are receiving to treat their lung cancer.

Participants will need to:

  • Sign a consent form to enter the trial.
  • Take the trial treatment as directed by the research team
  • Complete a participant diary to record when they took the trial treatment
  • Complete the Quality of Life and Health resource use questionnaires.
  • Female participants of childbearing potential must use adequate contraception during the trial and for at least 2 days after trial treatment has finished.
Read the detailed description

Venous thromboembolism (VTE) is common in lung cancer and results in worse quality of life, increased healthcare costs, increased morbidity, and mortality. VTE is also increased in lung cancer patients undergoing systemic anticancer therapy (SACT). VTE can be reduced using anticoagulation as thromboprophylaxis, but this is not the current standard of care for outpatients having SACT. The subcutaneous anticoagulant low molecular weight heparin can reduce VTE in lung cancer but can be inconvenient to take. Apixaban is a type of direct oral anticoagulant (DOAC) taken in tablet form and not requiring regular blood monitoring, which have a good safety profile and are licensed for other medical conditions. Whilst anticoagulants have been used for thromboprophylaxis in patients with cancer, the role of DOACs in ambulatory lung cancer patients is unanswered by the existing literature.

THROMBO-STOP is a multicentre, double blind, placebo-controlled, parallel group, two arm, phase 3 randomised clinical trial testing the efficacy of Apixaban to reduce VTE in ambulatory lung cancer patients undergoing SACT. There will be a process evaluation, acceptability study and economic evaluation. For this superiority trial, 1456 patients (728 per group) are required to have a 90% power of detecting, as significant with an alpha of 0.05 (two-sided), a decrease in the rate of VTE from 8.6% in the control group (placebo) to 4% in the intervention group (apixaban), assuming a 20% drop-out rate. The planned recruitment of 1456 patients would involve 34 sites.

THROMBO-STOP patients will be recruited over a 36-month period which includes a 12-month internal pilot among a projected 40% of sites.

Data from these elements inform our stop/go criteria. The pilot aims to i) assess recruitment rate and exclusions ii) to assess VTE event rate iii) to assess progression criteria.

The overall study time will be 60 months accounting for trial set up and analysis.

Participants will be recruited to the trial from NHS UK sites.

Randomisation will be via a secure online system (staffed telephone back-up during office hours) based at CRCTU, allocating participants in a 1:1 ratio to either apixaban 2.5mg BD or placebo. A minimisation algorithm will be used within the system to ensure balance in the intervention allocations over the following variables: age (\<70 or ≥70 ), sex (male or female) and cancer stage (III or IV). To avoid the possibility of the intervention allocation becoming predictable, a random element will be included in the algorithm.

02

Conditions studied

  • Thromboprophylaxis
03

In context

Lead sponsor

University of Birmingham is the lead sponsor of 182 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 16 years
  • Newly diagnosed locally advanced or primary lung cancer (histologically/ confirmed) or disease progression after complete or partial remission commencing a new course of SACT alone or as CRT
  • Ambulatory (receiving outpatient SACT)

Exclusion criteria

Exclusion criteria

  • to apixaban or to any of the listed SmPC
  • Active bleeding
  • Lesion or condition considered a significant risk factor for major bleeding
  • Hepatic disease associated with impaired synthetic function
  • count \< 50 x 109 /L
  • Elevated liver enzymes /AST > 2 x or total ≥ 1.5 x ULN
  • Renal failure ( \< 15ml/min)
  • Weight \< 40kg
  • Estimated \< 6 months
  • Continuous anticoagulation (e.g., unfractionated heparin, low molecular weight heparins, heparin derivatives and oral anticoagulants) for other medical conditions
  • The usage of medications with apixaban
  • Pregnancy
  • Breast feeding
  • Judgement by the Investigator that the participant is unsuitable to participate in the trial and the participant is unlikely to comply with trial procedures, restrictions and requirements
  • Inability to consent
  • Receiving SACT for potentially resectable / resectable lung cancer as part of or adjuvant treatment
  • SACT with significant potential DDI with apixaban (section 7.2.3)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,456 participants (estimated)

Study arms

  • Experimental
    Apixaban

    apixaban 2.5 mg twice a day for 6 months

    Drug: Apixaban

  • Placebo comparator
    Placebo

    apixaban matched placebo twice a day for 6 months

    Other: Placebo

Interventions

  • apixaban 2.5mg twice a day for 6 months

    Also known as: eliquis

  • OtherPlacebo

    Placebo twice a day for 6 months

06

What researchers measure

Primary outcomes

  1. 18.3.1.1 Objectively confirmed VTE

    Difference between a composite of objectively confirmed VTE and VTE-related death in participants with lung cancer, commencing SACT or CRT, when treated with 6 months of apixaban vs. placebo.

    Time frame: 6 months

Secondary outcomes

  1. Objectively confirmed VTE including all cause death

    Composite of: i. New proximal or distal DVT (symptomatic or incidental) of upper or lower limbs, iliac veins, inferior/superior vena cava or central venous catheter related thrombosis ii. Non-fatal PE (symptomatic or incidental) iii. Death from any cause

    Time frame: 6 months

  2. Bleeding outcomes

    * Major bleeding * Clinically relevant bleeding: Defined as the rate of participants experiencing at least one major bleeding and/or a clinically relevant non-major bleeding (CRNMB)

    Time frame: 6 months

  3. Net clinical benefit

    Net clinical benefit (NCB) combines the primary efficacy outcome and major bleeding or clinically relevant bleeding. NCB is defined as: \[the rate of VTE prevented by apixaban\] minus \[the rate of major or clinically relevant bleeding induced by apixaban\]. NCB= (VTE\_control-VTE\_apixaban ) - (Weighting × (Bleed\_apixaban-Bleed\_control )) VTE; the rate of objectively confirmed VTE or VTE related deaths (as defined for our primary outcome) Bleed; the rate of major bleeding or clinically relevant bleeding (as defined above). A default weighting factor of 1.0 will be used to represent an equal clinical weighting between the prevention of VTE by apixaban and the induction of major bleeding by apixaban, however supplementary analyses may be performed with a different weighting.

    Time frame: 6 months

  4. Proximal or distal DVT (symptomatic or incidental)

    The rate of proximal or distal DVT will be collected and the Odds Ratio of apixaban vs placebo will be reported.

    Time frame: 6 months

  5. Other rates of thrombosis

    The following thrombosis events will be investigated: * Arterial thromboembolism * Visceral thromboembolism

    Time frame: 6 months

  6. Survival outcomes

    * VTE-related death * All cause death * Vascular death

    Time frame: 6 months

  7. EQ-5D-5L questionnaire

    Questionnaires will be collected and the five subscale scores will be transformed to the summary index value using the value set(s) appropriate for the countries the trial opens in. Index values range from -0.285 and 1.00, with a higher score indicates a better quality of life. Median index values (along with subscale scores) will then be reported for apixaban and placebo groups, along with minimal important differences.

    Time frame: 6 months

  8. Time to VTE

    VTE events (objectively confirmed VTE or VTE-related deaths) will be presented as a time to event outcome (time to VTE).

    Time frame: 6 months

  9. Non-fatal PE

    The rate of non-fatal PEs will be collected and the Odds Ratio of apixaban vs placebo will be reported.

    Time frame: 6 months

  10. VTE-related death

    Time to VTE-related death will be collected and the Hazard Ratio of apixaban vs. placebo will be reported.

    Time frame: 6 months

  11. Global EORTC QLQ-C30 questionnaire

    Questionnaires will be collected and the mean global health status /QoL scale will be reported. This scale ranges from 0-100 with a higher score indicating a higher quality of life. Median health status/QoL (along with subscale scores) values will then be reported for apixaban and placebo groups, along with minimal important differences.

    Time frame: 6 months

  12. Lung cancer QLQ-LC29 questionnaire

    Questionnaires will be collected and subscales will be calculated and reported. All subscales range from 0-100, with a higher score indicating a higher quality of life. Median values will then be reported for apixaban and placebo groups, along with minimal important differences

    Time frame: 6 months

07

Study locations

8 of 8 sites recruiting
  • Dorset County Hospital
    Dorchester, DT1 2JY, United Kingdom
    Recruiting
    • Amelie Harle, Dr · Contact
  • Royal Devon and Exeter Hospital
    Exeter, EX2 5DW, United Kingdom
    Recruiting
    • Elizabeth Toy, Dr · Contact
  • James Paget Hospital
    Gorleston-on-Sea, NR31 6LA, United Kingdom
    Recruiting
    • May Han, Dr · Contact
  • Withybush General Hospital
    Haverfordwest, SA61 2PZ, United Kingdom
    Recruiting
    • Alison Brewster, Dr · Contact
  • Queen Elizabeth Hospital
    London, SE18 4QH, United Kingdom
    Recruiting
    • Daniel Hughes, Dr · Contact
  • Queens Hospital Romford
    Romford, RM7 0AG, United Kingdom
    Recruiting
    • Kathryn Tarver, Dr · Contact
  • Royal Shrewsbury Hospital
    Shrewsbury, SY3 8XQ, United Kingdom
    Recruiting
    • Anirban Chatterjee, Dr · Contact
  • Kings Mill Hospital
    Sutton in Ashfield, NG17 4JL, United Kingdom
    Recruiting
    • Ananth Sivanandan, Dr · Contact
08

References and documents

Individual participant data

Plan to share: Yes — There is a plan to make IPD and related data dictionaries available after the end of the study.

Supporting information: Study protocol

Time frame: IPD and supporting information will be available within 12 months of the primary publication.

Access criteria: Data anonymised in compliance with the Information Commissioners Office requirements, using a procedure based on guidelines from the Medical Research Council (MRC) Methodology Hubs and Information Commissioners Office, will be available for sharing with researchers outside of the trials team within 12 months of the primary publication.

Data sharing details ↗ · www.birmingham.ac.uk

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2026 (actual). Primary completion is estimated for Oct 2029, 42 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: start Mar 2026 → Apr 2026 and primary completion Sep 2029 → Oct 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2025
First posted
Sep 8, 2025
StartActual
Apr 28, 2026was Mar 2026
Primary completionEst.
Oct 30, 2029was Sep 2029
CompletionEst.
Mar 30, 2030
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 28, 2026
Sites
8 sites added, 1 site removed
Show 8 added (8 United Kingdom)
  • Dorset County Hospital · Dorchester, United Kingdom
  • Royal Devon and Exeter Hospital · Exeter, United Kingdom
  • James Paget Hospital · Gorleston-on-Sea, United Kingdom
  • Withybush General Hospital · Haverfordwest, United Kingdom
  • Queen Elizabeth Hospital · London, United Kingdom
  • Queens Hospital Romford · Romford, United Kingdom
  • Royal Shrewsbury Hospital · Shrewsbury, United Kingdom
  • Kings Mill Hospital · Sutton in Ashfield, United Kingdom
Show 1 removed
  • University of Birmingham · Birmingham, United Kingdom
Sep 28, 2026
Start date
Mar 2, 2026→Apr 28, 2026 (actual)
Sep 28, 2026
Primary completion
Sep 30, 2029→Oct 30, 2029
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Not yet recruiting→Recruiting
    8 sites added, 1 site removed
    Show 8 added (8 United Kingdom)
    • Dorset County Hospital · Dorchester, United Kingdom
    • Royal Devon and Exeter Hospital · Exeter, United Kingdom
    • James Paget Hospital · Gorleston-on-Sea, United Kingdom
    • Withybush General Hospital · Haverfordwest, United Kingdom
    • Queen Elizabeth Hospital · London, United Kingdom
    • Queens Hospital Romford · Romford, United Kingdom
    • Royal Shrewsbury Hospital · Shrewsbury, United Kingdom
    • Kings Mill Hospital · Sutton in Ashfield, United Kingdom
    Show 1 removed
    • University of Birmingham · Birmingham, United Kingdom
    Start date Mar 2, 2026→Apr 28, 2026 (now actual)
    Primary completion Sep 30, 2029→Oct 30, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07160686
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Apr 28, 2026
Primary completion
Oct 30, 2029 (estimated)
Completion
Mar 30, 2030 (estimated)
Last update
Sep 28, 2026

Study contacts

Ann Pope, PhD
Contact
THROMBO-STOP@trials.bham.ac.uk
+44 4146372
Sophia Magwaro, BSc
Contact
THROMBO-STOP@trials.bham.ac.uk
Michael Newnham, MBChB, MSc, MRCP, PhD
principal investigator · University of Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion